

AMENDMENTS TO THE CLAIMS

1. **(Withdrawn)** A cell-containing preparation comprising a cell which has a DNA having a base sequence represented by SEQ ID NO: 1 or 2 or a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO: 1 or 2 under stringent conditions and a fibrous protein.
2. **(Withdrawn)** The cell-containing preparation according to claim 1, wherein the cell is an epithelial cell of the oral mucosa, a skin cell or a fibroblast.
3. **(Withdrawn)** The cell-containing preparation according to claim 1, wherein the fibrous protein is collagen.
4. **(Withdrawn)** The cell-containing preparation according to claim 1, wherein the cells are deposited on the surface of the fibrous protein.
5. **(Withdrawn)** The cell-containing preparation according to claim 1, wherein the cell is a transformant.
6. **(Withdrawn)** The cell-containing preparation according to claim 5, wherein the transformant is transformed with a recombinant expression vector.
7. **(Withdrawn)** The cell-containing preparation according to claim 6, wherein the recombinant expression vector is adeno-associated virus (AAV), retrovirus, poxvirus, herpes virus, herpes simplex virus, lentivirus (HIV), Sendai virus, Epstein-Barr virus (EBV), vaccinia virus, polio virus, sindbis virus, SV40 or plasmid.
8. **(Withdrawn)** The cell-containing preparation according to claim 1 capable of forming a peptide encoded by a DNA having a base sequence represented by SEQ ID NO: 1 or 2, or by a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO: 1 or 2 under

stringent conditions.

9. (Withdrawn) The cell-containing preparation according to claim 1 further containing a mesh sheet comprising a biodegradable resin.

10. (Withdrawn) The cell-containing preparation according to claim 9, wherein the biodegradable resin is polyglycolic acid.

11. (Withdrawn) The cell-containing preparation according to claim 1, which is an anticancer agent or a cancer metastasis inhibitor.

12. (Withdrawn) The cell-containing preparation according to claim 11, which is an anticancer agent or a metastasis inhibitor for ovarian cancer, pancreatic cancer, stomach cancer, gall bladder cancer, kidney cancer, prostate cancer, breast cancer, esophageal cancer, liver cancer, oral cavity cancer, colon cancer, large intestine cancer, sarcoma, glioma or melanoma.

13. (Withdrawn) The cell-containing preparation according to claim 1, which is an angiogenesis inhibitor.

14. (Withdrawn) A method for inhibiting growth, invasion and metastasis of cancers or for inhibiting angiogenesis, which comprises administering a cell-containing preparation comprising a cell which has a DNA having a base sequence represented by SEQ ID NO: 1 or 2 or a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO: 1 or 2 under stringent conditions and a fibrous protein to a mammal.

15. (Withdrawn) A method for producing a cell-containing preparation, which comprises culturing a cell on the surface of a fibrous protein and transforming the cultured cells with a recombinant expression vector comprising a DNA having a base sequence represented by SEQ ID NO: 1 or 2, or with a recombinant expression vector comprising a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO: 1 or 2 under stringent conditions.

16. (Withdrawn) A method for producing a cell-containing preparation, which comprises preparing a fibrous protein sheet by coating a fibrous protein onto a mesh sheet comprising a biodegradable resin; culturing a cell on the surface of the fibrous protein sheet obtained; and transforming the cultured cells with a recombinant expression vector comprising a DNA having a base sequence represented by SEQ ID NO: 1 or 2, or with a recombinant expression vector comprising a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO: 1 or 2 under stringent conditions.

17. (Withdrawn) A method for producing a cell-containing preparation, which comprises transforming the cells with a recombinant expression vector comprising a DNA having a base sequence represented by SEQ ID NO: 1 or 2, or with a recombinant expression vector comprising a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO: 1 or 2 under stringent conditions, and mixing the resulting transformant cells with a fibrous protein.

18. (Withdrawn-currently amended) The ~~cell-containing preparation~~method according to claim 14, wherein the cell is an epithelial cell of the oral mucosa, a skin cell or a fibroblast.

19. (Withdrawn-currently amended) The ~~cell-containing preparation~~method according to claim 14, wherein the fibrous protein is collagen.

20. (Withdrawn-currently amended) The ~~cell-containing preparation~~method according to claim 14, wherein the cells are deposited on the surface of the fibrous protein.

21. (Withdrawn-currently amended) The ~~cell-containing preparation~~method according to claim 14, wherein the cell is a transformant.

22. (Withdrawn-currently amended) The ~~cell-containing preparation~~method according to claim 21, wherein the transformant is transformed with a recombinant expression vector.

23. (Withdrawn-currently amended) The cell-containing preparationmethod according to claim 22, wherein the recombinant expression vector is adeno-associated virus (AAV), retrovirus, poxvirus, herpes virus, herpes simplex virus, lentivirus (HIV), Sendai virus, Epstein-Barr virus (EBV), vaccinia virus, polio virus, sindbis virus, SV40 or plasmid.

24. (Withdrawn-currently amended) The cell-containing preparationmethod according to claim 14, wherein the cell-containing preparation is capable of forming a peptide encoded by a DNA having a base sequence represented by SEQ ID NO: 1 or 2, or by a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO: 1 or 2 under stringent conditions.

25. (Withdrawn-currently amended) The cell-containing preparationmethod according to claim 14, wherein the cell-containing preparation further contains a mesh sheet comprising a biodegradable resin.

26. (Withdrawn-currently amended) The cell-containing preparationmethod according to claim 25, wherein the biodegradable resin is polyglycolic acid.

27-29. (Canceled)

30. (New) A method for inhibiting growth, invasion and metastasis of cancer or for inhibiting angiogenesis, which comprises administering a cell-containing preparation comprising a cell which has a DNA having a base sequence represented by SEQ ID NO:2 or a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO:2 under stringent conditions and a fibrous protein to a mammal.

31. (New) The method according to claim 30, wherein the cell is an epithelial cell of the oral mucosa, a skin cell or a fibroblast.

32. (New) The method according to claim 30, wherein the fibrous protein is collagen.

33. (New) The method according to claim 30, wherein the cells are deposited on the surface of the fibrous protein.

34. (New) The method according to claim 30, wherein the cell is a transformant.

35. (New) The method according to claim 34, wherein the transformant is transformed with a recombinant expression vector.

36. (New) The method according to claim 35, wherein the recombinant expression vector is adeno-associated virus (AAV), retrovirus, poxvirus, herpes virus, herpes simplex virus, lentivirus (HIV), Sendai virus, Epstein-Barr virus (EBV), vaccinia virus, polio virus, sindbis virus, SV40 or plasmid.

37. (New) The method according to claim 30, wherein the cell-containing preparation is capable of forming a peptide encoded by a DNA having a base sequence represented by SEQ ID NO:2, or by a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO:2 under stringent conditions.

38. (New) The method according to claim 30, wherein the cell-containing preparation further contains a mesh sheet comprising a biodegradable resin.

39. (New) The method according to claim 38, wherein the biodegradable resin is polyglycolic acid.

40. (New) The method according to claim 30, wherein the cell is an epithelial cell of the oral mucosa, and is a transformant transformed with a recombinant expression adeno-associated virus (AAV) vector.